OBJECTIVE： To investigate the effects of Cynomorium songaricum extract on liver fibrosis model rats and its mechanism. METHODS： 90 SD rats were randomly divided into normal group， model group， colchicine group （positive drug， 0.2 mg/kg）， C. songaricum extract low-dose， medium-dose and high-dose groups （50， 100， 200 mg/kg）， with 15 rats in each group. Except for normal group， those groups were given carbon tetrachloride to induce liver fibrosis model. After modeling， treatment groups were given relevant medicine intragastrically， and normal group and model group were given normal saline intragastrically， once a day， for consecutive 6 weeks. After treatment， serum liver function index [AST， ALT， ALP， CK] of rats were detected. The pathological changes in the livers of rats were observed by HE and Masson staining； the expression of TGF-β1 in the livers and serum of rats were detected and liver index was calculated. RESULTS： Compared with normal group， liver index， AST， ALT， CK， ALP， the level of TGF-β1 in serum and liver were increased in model group， with statistical significance （P＜0.05）. Pathological results showed that fibrosis lesion was found in liver tissue of rats in model group. Compared with model group， those index of colchicine group， C. songaricum extract medium-dose and high-dose groups were improved significantly and ALT of C. songaricum extract low-dose group was improved obviously， except for serum levels of ALP and CK in C. songaricum extract medium-dose groups. The degree of fibrosis was relieved in treatment groups. CONCLUSIONS： C. songaricum extract can improve liver fibrosis to certain extent， which may be related with inhibiting the expression of TGF-β1.